Today, specialists from the University of Cambridge presented their new unique test in virtual reality, aimed at identifying with high probability the first signs of the development of such a neurodegenerative disease as Alzheimer's syndrome. Experts have been working on this test for a long time and at the moment they have presented its most perfect form – the test itself is aimed at checking the accuracy of the entorhinal cortex, which first suffers from gradually increasing in intensity signs of neurodegeneration, in particular, different orientation space.
And this is precisely what this new test is oriented to – it primarily tests the patient’s ability to navigate in virtual space using a virtual reality helmet and controllers connected to the system. According to preliminary studies, standard diagnostic tests to determine the severe form of neurodegeneration often confuse it with mild cognitive impairment such as MCI – when a person begins to navigate in space with age.
To avoid this confusion, developers selected 45 patients with MCI disorder and examined their biomarkers for compliance with Alzheimer's syndrome. Then, having conducted the diagnostic test itself in a virtual environment, it was determined that those patients whose biomarkers coincide to a greater extent with the biomarkers of patients with Alzheimer's syndrome are much worse at coping with the tasks of orientation in the artificial space of the virtual environment.
Thus, a new diagnostic test in virtual space from specialists in neurodegeneration from the University of Cambridge shows that it is possible to recognize the various first signs of such a disorder more effectively if more effective and modern diagnostic measures are used as such. So it remains to wait for the subsequent improvement of the test functionality.